Open AccessA reflective process led by a family physician to develop a renal-protection surveillance tool for HIV patients newly started on dolutegravir
Author(s) -
Junaid Omar,
Izak Loftus,
Nabeelah Vallie,
Richard B Whitmore,
Gaironesa Solomon,
Michelle Powell,
Samela Mniki,
Mosedi Namane
Publication year - 2021
Publication title -
african journal of primary health care and family medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 20
eISSN - 2071-2936
pISSN - 2071-2928
DOI - 10.4102/phcfm.v13i1.3088
Subject(s) - dolutegravir , vanguard , medicine , regimen , pandemic , excellence , pre exposure prophylaxis , intensive care medicine , covid-19 , human immunodeficiency virus (hiv) , family medicine , antiretroviral therapy , disease , viral load , infectious disease (medical specialty) , archaeology , men who have sex with men , syphilis , law , political science , history
A group of Vanguard Community Health Centre doctors embarked on a Health System's Improvement (HSI) project with the aim of reducing harm to renal function in patients who were either commenced on or switched to a dolutegravir (DTG)-based antiretroviral therapy (ART) regimen since 2019, when the usual monitoring and evaluation of ART-regimen switches were disrupted by the coronavirus disease 2019 (COVID-19) pandemic. This intended harm-reduction exercise, involving a reflective process that was facilitated by the family physician, led to the development of a Vanguard Renal Protection Surveillance tool, which is now used at Vanguard to detect and prevent renal decline.